glp-1 amgen ADA: talks Repatha, hurdles as obesity plan advances From Fat Burn to Muscle
Description
NASH remains a complex, multifaceted issue with no standard treatment that is currently available 3
The potential of semaglutide and similar medications to aid in reducing alcohol consumption opens new avenues for treating alcohol use disorder
Reasonable & Competitive Price
Another factor to consider is long-term benefits with weight-loss or possible disease improvement would require continued use of GLP-1 agonist in addition to other IBD treatment options, which can be an additional financial or emotional burden on patients that would need further exploring as well.
2025 Apr 7;23(1):18
A critical challenge for future clinical studies will be the robust assessment of treatment effects on in situ fibrosis
